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Background: The chemokine receptor 4 (CXCR4) is an important molecular target
for both visualization and therapy of tumors. The aim of the present study was the
synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-targeting peptide for
positron emission tomography (PET) imaging of CXCR4 expression in vivo.
Methods: For this purpose, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid
(NODAGA), or 1,4,7-triazacyclononane-triacetic acid (NOTA) was conjugated to the
highly affine CXCR4-targeting pentixather scaffold. Affinities were determined using
Jurkat T-lymphocytes in competitive binding assays employing [125I]FC131 as the
radioligand. Internalization and efflux studies of [64Cu]NOTA-pentixather were
performed in chem-1 cells, stably transfected with hCXCR4. The stability of the tracer
was evaluated in vitro and in vivo. Small-animal PET and biodistribution studies at
different time points were performed in Daudi lymphoma-bearing severe combined
immunodeficiency (SCID) mice.
Results: [64Cu]NOTA-pentixather was rapidly radiolabeled at 60 °C with high
radiochemical yields ≥90% and purities >99%. [64Cu]NOTA-pentixather offered the
highest affinity of the evaluated peptides in this study (IC50 = 14.9 ± 2.1 nM), showed
efficient CXCR4-targeting in vitro and was stable in blood and urine with high resistance
to transchelation in ethylenediaminetetraacetic acid (EDTA) challenge studies. Due to the
enhanced lipophilicity of [64Cu]NOTA-pentixather (logP = -1.2), biodistribution studies
showed some nonspecific accumulation in the liver and intestines. However, tumor
accumulation (13.1 ± 1.5% ID/g, 1.5 h p.i.) was CXCR4-specific and higher than in all other
organs and resulted in high resolution delineation of Daudi tumors in PET/CT images
in vivo.
Conclusions: [64Cu]NOTA-pentixather was fast and efficiently radiolabeled, showed
effective CXCR4-targeting, high stability in vitro and in vivo and resulted in high
resolution PET/CT images accompanied with a suitable biodistribution profile, making
[64Cu]NOTA-pentixather a promising tracer for future application in humans.
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Physiologically, the chemokine receptor 4 (CXCR4) and its only endogenous ligand
CXCL12 act through G-protein signaling which leads to chemotaxis, cell adhesion, sur-
vival, and proliferation (Kuil et al. 2012a; Hattermann & Mentlein 2013; Burger &
Kipps 2006). In cancer, the CXCR4-CXCL12 axis is involved in tumor growth and
progression, invasion and organ-specific metastasis, therapy resistance as well as recur-
rence (Chatterjee et al. 2014; Burger & Peled 2009; Domanska et al. 2013). Therefore,
CXCR4 is an attractive molecular target, both for therapeutic interventions and for
noninvasive quantification of CXCR4 expression, the latter providing important infor-
mation on the stage and kinetics of the disease. In recent years, a variety of high-
affinity CXCR4-targeted imaging probes have been developed for this application,
with a focus on targeted peptides, including derivatives of T140 labeled with various
radionuclides (George et al. 2014; Yan et al. 2015; Jacobson et al. 2010; Tamamura
et al. 2003; Tamamura et al. 1998; Jacobson et al. 2012; Hanaoka et al. 2006), FC131
(Gourni et al. 2011; Demmer et al. 2011a; Demmer et al. 2011b; Tanaka et al. 2010;
Poschenrieder et al. 2016a), and small molecules such as AMD3100 (plerixafor)-based
derivatives, that have been labeled with 64Cu (Weiss et al. 2012; De Silva et al. 2011;
Nimmagadda et al. 2010; Jacobson et al. 2009; Woodard et al. 2014), 18F (Oltmanns
et al. 2011), 11C (Hartimath et al. 2014), and 68Ga (Poty et al. 2016). Summaries of
CXCR4-targeting probes have recently been reported in excellent reviews (Kuil et al.
2012b; Debnath et al. 2013; Weiss & Jacobson 2013). Amongst CXCR4-targeted
imaging agents, [68Ga]pentixafor (Gourni et al. 2011; Demmer et al. 2011a) holds a
prominent position, because its excellent CXCR4-targeting properties and fast renal ex-
cretion allow for high contrast PET imaging of CXCR4 expression in humans. Combined
with a favorable dosimetry (Herrmann et al. 2015) these properties have paved the way
for first currently ongoing clinical studies (Philipp-Abbrederis et al. 2015; Wester et al.
2015; Lapa et al. 2016a; Lapa et al. 2016b; Vag et al. 2016; Herhaus et al. 2016).
Recently, a corresponding therapeutic analog with a slightly modified peptide back-
bone, [177Lu]pentixather, has been introduced, and in first-in-man studies in patients
with multiple myeloma, CXCR4-targeted endoradiotherapy using [177Lu]pentixather
produced promising metabolic responses (Schottelius et al. 2015; Herrmann et al.
2016). [177Lu]pentixather thus complements diagnostic imaging with [68Ga]pentixafor
to a first CXCR4-directed theranostic concept.
However, due to the sensitivity of the pentixafor scaffold towards even small struc-
tural modifications such as radiometal exchange in the DOTA chelator (Poschenrieder
et al. 2016b), different dedicated precursors are required for diagnostic and therapeutic
applications. In this context, copper radionuclides represent an interesting imaging
option. Although 64Cu (t1/2 = 12.7 h, β
+ = 19%, Eβ
+
max = 656 keV, β
- = 38%, Eβ-max =
578 keV) decays by both β+ and β- emission, its low β+ energy, which is comparable to
that of 18F (Eβ + max = 633 keV), provides high spatial resolution in PET imaging
(Williams et al. 2005) and its comparably long half-life is advantageous for performing
kinetic PET imaging studies over extended periods of time.
To date, only a few 64Cu-labeled CXCR4-ligands have been reported. They are either
based on the bicyclam AMD3100 (Weiss et al. 2012; De Silva et al. 2011; Nimmagadda
et al. 2010; Jacobson et al. 2009) or chelator-conjugated T140 analogs (Jacobson et al.
2012; Jacobson et al. 2011). Despite promising in vitro CXCR4 targeting properties, the
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accumulation and retention of 64Cu activity in the excretion organs (20-40% ID/g),
especially in liver and kidneys, hinting -at least partly- towards a limited in vivo stability
of the respective 64Cu-complexes.
Thus, to be able to nevertheless exploit the favorable radionuclide characteristics of
64Cu, this study was aimed at developing a 64Cu-labeled CXCR4-targeted probe, which
combines high 64Cu-complex stability with the favorable in vivo pharmacokinetics of
pentixafor-based ligands. Thermodynamically stable (Bevilacqua et al. 1987; Wu et al.
2016; Jones-Wilson et al. 1998) and, depending on the conjugated biomolecule, kinetic-
ally inert (Zarschler et al. 2014; Dearling et al. 2011) 64Cu complexes are formed with a
variety of chelators (Cai & Anderson 2014; Wadas et al. 2007), including NOTA.
As first demonstrated for [177Lu]pentixather, the pentixather scaffold is substan-
tially less sensitive towards structural modifications than pentixafor (Schottelius
et al. 2015; Herrmann et al. 2016). Since NOTA forms stable Cu2+-complexes
and a NOTA-for-DOTA exchange retained the favorable CXCR4-targeting proper-
ties of pentixather conjugates (Poschenrieder et al. 2016a), we were interested in
the corresponding 64Cu-conjugates for PET imaging of CXCR4 expression
in vivo. The possibility to further extend this tracer concept towards radiolabeling
with copper radionuclides was now exemplarily evaluated by the detailed in vitro
and in vivo investigation of 64Cu-labeled NOTA- and NODAGA-analogs of
pentixather (Fig. 1).Results
Radiolabeling
Under standard labeling conditions, [64Cu]NOTA-pentixather was obtained in radio-
chemical yields ≥90%. Radiochemical purities after C8-light purification were >99%, as
confirmed by radio-TLC. The specific activity was 43 GBq/μmol.Fig. 1 Chemical structures of [Cu]NOTA and [Cu]NODAGA-pentixather
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[64Cu]NOTA-pentixather shows a logP of -1.2. Compared to its close structural analog
[18F]AlF-NOTA-pentixather (log P = -1.4, (Poschenrieder et al. 2016a)), the 64Cu-labeled
NOTA-peptide is slightly more lipophilic, whereas its lipophilicity is increased by more than
an order of magnitude compared to [68Ga]pentixafor (log P = -2.90 (Gourni et al. 2011)).Determination of CXCR4 affinities (IC50)
The CXCR4 affinities of [natCu]NOTA- and [natCu]NODAGA-pentixather as well as of
the corresponding metal free chelator-conjugated peptides were determined in a com-
petitive binding assay using standard conditions (CXCR4-expressing Jurkat
T-lymphocytes (4 × 105 cells per sample) and [125I]FC131 as the radioligand
(Poschenrieder et al. 2016a; Wester et al. 2015; Schottelius et al. 2015; Poschenrieder
et al. 2016b)) (Table 1). Data for [natGa]pentixafor and FC131 are included as a refer-
ence. As already observed for [natGa]pentixafor, metal complexation leads to enhanced
CXCR4 affinity, both for [natCu]NOTA-pentixather and for [natCu]NODAGA-pentix-
ather. Compared to [natGa]pentixafor, however, [natCu]NOTA-pentixather showed
almost twofold higher CXCR4 affinity, while it is reduced by a factor of two in the case
of [natCu]NODAGA-pentixather.Cell uptake and efflux studies
Figure 2a shows the CXCR4-specific total cellular uptake and internalization of
[64Cu]NOTA-pentixather into Chem-1 cells, stably transfected with hCXCR4. The pref-
erential use of this adherent cell line for the internalization and externalization studies
was based on our previous observation that the determination of cellular uptake kinet-
ics in suspension cells (such as Jurkat or Daudi cells (Wester et al. 2015)) is oftentimes
biased by the experimental conditions (repeated centrifugation and resuspension steps),
challenging cell viability and thus leading to inconsistent and irreproducible results.
This effect was not encountered using Chem-1 cells. As shown in Fig. 2a, the totalTable 1 Affinities (IC50) of different Cu
2+-labeled pentixafor derivatives, [natCu]NOTA,
[natCu]NODAGA-pentixather, and the corresponding metal-free precursors to human CXCR4. FC131
and [68Ga]pentixafor are included as reference compounds. Competitive binding studies were
carried out using Jurkat T-cell leukemia cells (400.000 cells/sample) and [125I]FC131 as the
radioligand
Compound IC50 [nM]
FC131 9.9 ± 2.4a
[natGa]pentixafor (DOTA) 24.8 ± 2.5a
[natCu]DOTAGA-pentixafor 1165 ± 220a
[natCu]NOTA-pentixafor 46.1 ± 26a
[natCu]NODAGA-pentixafor 343 ± 10a
[natCu]DTPA-pentixafor 175 ± 66a
NOTA-pentixather 27.5 ± 2.1
[natCu]NOTA-pentixather 14.9 ± 2.1
NODAGA-pentixather 64.9 ± 6.5
[natCu]NODAGA-pentixather 47.5 ± 1.8
aref (Poschenrieder et al. 2016b)
Data are means ± SD from a minimum of three separate determinations
Fig. 2 a Total cellular uptake and internalization and b efflux kinetics of [64Cu]NOTA-pentixather in
Chem-1 cells stably transfected with hCXCR4; 150000 cells/well were incubated with [64Cu]NOTA-pentixather
(1 nM) at 37 °C in medium (5% BSA). The total cellular activity was corrected for non-specific binding in the
presence of 100 μM AMD3100. Data are means ± SD
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approximately 12 and 22% of the added activity after 15 and 120 min, respectively.
Internalization reaches a maximum after 30 min (~10%) and decreases to ~ 5% after
120 min. An exemplary efflux study is shown in Fig. 2b and reveals that 28% of the initial
cellular [64Cu]NOTA-pentixather activity are retained after 120 min of externalization.Biodistribution studies
Biodistribution data of [64Cu]NOTA-pentixather at 1.5 h p.i. (n = 5, black bars) and
24 h p.i. (n = 6, grey bars) in Daudi-lymphoma-bearing SCID mice are summarized in
Fig. 3. Given the fact that Jurkat cells, which are generally used for the determination
of CXCR4 affinity, are not tumorigenic in mice and to ensure comparability of data
with previous studies (Poschenrieder et al. 2016a; Wester et al. 2015; Schottelius et al.
2015), the Daudi lymphoma model was also used in this study. Blood clearance of
[64Cu]NOTA-pentixather was fast (1.1 ± 0.2% ID/g at 1.5 h p.i.), and activityFig. 3 Biodistribution of [64Cu]NOTA-pentixather at 1.5 h (tracer only, black bars, n= 5) and 24 h p.i. (grey bars,
n= 6) in Daudi xenograft-bearing CB-17 SCID mice. Mice were injected with 5.2 MBq [64Cu]NOTA-pentixather
(122 pmol/0.160 μg peptide; AS = 43 GBq/μmol). Non-specific tracer accumulation was determined by coinjection
of 2 mg/kg AMD3100 (50 μg/mouse; white bars, n= 3)
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of [64Cu]NOTA-pentixather compared to [68Ga]pentixafor (logP = -2.90 (Gourni et al.
2011)), a certain extent of hepatobiliary excretion and thus non-specific accumulation
in the liver and intestines were observed (7.2 ± 1.1 and 5.0 ± 2.8% ID/g, respectively),
while activity accumulation in the kidney was comparably low (3.8 ± 0.5% ID/g). Tumor
uptake of [64Cu]NOTA-pentixather was significantly higher than tracer accumulation
in all other organs (13.1 ± 1.5% ID/g), underlining its excellent CXCR4 targeting effi-
ciency. Coinjection of 2 mg/kg AMD3100 (Fig. 3, white bars) resulted in a reduction of
tumor uptake by 88% (1.5 h p.i.), demonstrating the high CXCR4-specificity of
[64Cu]NOTA-pentixather accumulation in the lymphoma xenograft. The resulting
tumor-to-organ ratios at 1.5 and 24 h p.i. are summarized in Fig. 4. While the tumor-
to-background ratios for most tissues remain unchanged or decrease within the
observation period, t/blood and t/intestine ratios increase 1.3 and 2.4 fold between 1.5
and 24 h p.i., respectively.Small animal PET imaging
Representative PET/CT images of [64Cu]NOTA-pentixather in Daudi-lymphoma bear-
ing SCID mice at 1 h, 3.5 h, and 24 h p.i. are shown in Fig. 5. Besides high and
CXCR4-specific uptake of [64Cu]NOTA-pentixather in the Daudi lymphoma xenograft,
some background activity uptake is observed in the liver, the gall bladder, and the intes-
tines. Upon coinjection with 50 μg AMD3100, tumor accumulation is reduced to
background levels (Fig. 5b), demonstrating that tumor uptake of [64Cu]NOTA-pentix-
ather is almost exclusively CXCR4-mediated.
Figure 6 shows time-activity-curves (TACs) obtained by [64Cu]NOTA-pentixather
PET for the heart (blood pool), kidney, liver, muscle, and tumor and further illustrates
the rapid and continuous accumulation of [64Cu]NOTA-pentixather in the Daudi xeno-
graft, accompanied by rapid background clearance.Metabolite analysis and EDTA challenge
To investigate the in vitro stability of [64Cu]NOTA-pentixather, the tracer was incu-
bated both in human serum at 37 °C and in 0.1 M EDTA at pH = 2.5 and physiologicalFig. 4 Tumor-to-organ ratios of [64Cu]NOTA-pentixather 1.5 and 24 h p.i. (black and grey bars, respectively)
Fig. 5 PET/CT imaging (maximal intensity projections (MIP)) of Daudi xenograft bearing CB-17 SCID mice at
1 h p.i. of 5.2 MBq [64Cu]NOTA-pentixather; (a) tracer only, (b) coinjection of 2 mg/kg AMD3100; (c) and (d)
images at 3.5 and 24 h p.i. (tracer only)
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remained stable over 24 h in human serum (>99% intact 64Cu-chelate). Additionally,
high resistance towards transchelation was demonstrated in challenge experiments with
excess EDTA (0.1 M) (logKCu-EDTA = 18.7 (Jones-Wilson et al. 1998)), since over 90% of
[64Cu]NOTA-pentixather were found to remain intact, even at pH 2.5 after 24 h.
The in vivo stability of the tracer was investigated via metabolite studies in mice.
Radio-HPLC analysis of urine and blood as well as tissue homogenates from liver
and kidney showed that 98% intact [64Cu]NOTA-pentixather were present in blood
and urine, while 68 and 24% intact tracer were found in liver and kidney,
respectively.Fig. 6 Time-activity-curves of heart, kidney, liver, muscle, and tumor after injection of [64Cu]NOTA-pentixather
into Daudi lymphoma-bearing SCID mice
Fig. 7 In vitro stability of [64Cu]NOTA-pentixather as a function of incubation time. [64Cu]NOTA-pentixather
was incubated in human serum at 37 °C (■) or 0.1 M EDTA at different pH values (7.4: ▲, 2.5: ●) at 25 °C
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Excellent reviews on the multiple facets of copper chelation chemistry highlight the
various aspects that need to be taken into account in the development of copper-
radiopharmaceuticals with suitable in vivo biodistribution profiles (Cai & Anderson
2014; Wadas et al. 2007; Anderson & Ferdani 2009; Tegoni et al. 2014).
Despite reasonable thermodynamic stability, macrocyclic Cu2+ complexes, e.g.
DOTA-complexes, are oftentimes prone to in vivo dissociation and transchelation due
to challenge with e.g. endogenous metal ions or metal-binding proteins under very di-
lute tracer concentrations (Jones-Wilson et al. 1998; Kukis et al. 1994), leading to
significant non-specific activity accumulation in the liver or other non-target tissues
(Bass et al. 2000; Boswell et al. 2004) at least at later time points. Thus, copper com-
plexes with high kinetic inertness, which are formed with specific macrocyclic
nonbridged (e.g. cyclen and cyclam derivatives, including 1,4,8,11-tetraazacyclodode-
cane-1,4,8,11-tetraacetic acid (TETA), NOTA or NODAGA), bridged macrocyclic
chelators, (e.g. 1,8-ethylene cross-bridged cyclam derivatives like CB-TE2A), or
sarcophagine-based chelators (e.g. diamSar) are primarily used for the preparation of
copper radiopharmaceuticals (Cai & Anderson 2014; Wadas et al. 2007; Wadas
et al. 2010).
Unfortunately, Cu2+-complexes of different pentixafor derivatives (Table 1) showed
disappointing affinities towards CXCR4. However, due to structural modifications of
the pentixafor scaffold, we found a conjugate, [Al18F2+]NOTA-pentixather, which dem-
onstrated promising CXCR4-targeting properties in vitro and in vivo as well as suitable
pharmacokinetics (Poschenrieder et al. 2016a). Thus, NOTA-pentixather as well as the
corresponding NODAGA-analog were evaluated in this study as precursors for novel
CXCR4-targeted 64Cu-radiopharmaceuticals. Because of the comparably low CXCR4
affinity of the [natCu]NODAGA conjugate (Table 1), only [natCu]NOTA-pentixather
(Fig. 1) was selected for further preclinical evaluation.
Although [64Cu]NOTA chelates are generally of high stability (Zarschler et al. 2014;
Dearling et al. 2011; Prasanphanich et al. 2007), dissociation of 64Cu has been reported
to be influenced by the conjugated biomolecule, e.g. by exposed amino acid residues
that compete with the chelator (Zarschler et al. 2014; Kukis et al. 1994; Boswell et al.
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cubation, acid-promoted dissociation studies, and EDTA-challenge experiments re-
sulted in almost no transchelation when challenged and no albumin association. In vivo
investigations demonstrated ≥98% intact 64Cu-chelate in urine and blood, whereas
transchelation of 64Cu in kidney and liver occurred; Cu-dependent enzymes (e.g. super-
oxide dismutase (SOD)) or proteins (e.g. caeruloplasmin and metallothionein) are
highly abundant in liver or kidney and are most probably responsible for inferior
kinetic inertness of the tracer in these organs (Bass et al. 2000; McArdle et al. 1999;
Terao & Owen 1973; Blower et al. 1996; Valentine et al. 1999; Musci et al. 1999).
Transchelation of [64Cu]TETA-octreotide to SOD (Bass et al. 2000) and transfer of
copper from a 67Cu-labeled antibody to ceruloplasmin (Mirick et al. 1999) were previ-
ously reported, accompanied by increasing blood activity levels, indicating the
re-release of 64Cu from liver to the blood. However, this was not the case for
[64Cu]NOTA-pentixather, which showed no dissociation in blood, both in vitro and
in vivo, and displayed increasing tumor-to-blood ratios over time.
Moreover, activity accumulation in excretory organs 1.5 h p.i. was similar to that of
[18F]AlF-NOTA-pentixather (logP = -1.4); hence, the shift towards hepatobiliary excre-
tion and thus unspecific accumulation in the liver and intestines can be attributed to
its slightly enhanced lipophilicity (logP = -1.2) rather than the instability of the 64Cu-
chelate. Although NOTA causes a slightly enhanced lipophilicity compared to the
parental compound [68Ga]pentixafor (logP = -2.9), NOTA offered suitable properties as
chelator in novel pentixafor-based 64Cu-radiopharmaceuticals.
Although no transchelation or metabolization assays have been performed for the re-
ported 64Cu-labeled T140 derivatives (T140-2D, DOTA-, and NOTA-T140-NFB), the
authors suggest the formation of metabolites of the labeled peptides in vivo because, in
contrast to [18F]T140, all of them shared high, long-lasting, and mostly unspecific
uptake in liver and kidneys (Jacobson et al. 2012; Jacobson et al. 2011) which impairs
their use as ideal PET imaging agent.
Besides the tetradecapeptides, two AMD-based CXCR4-targeting 64Cu-labeled tracers
have been reported, namely [64Cu]AMD3100 and [64Cu]AMD3465 (Weiss et al. 2012;
De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009). The latter providing
very high and specific tumor uptake; however both tracers also show high uptake in
the liver and kidneys. In contrast to 64Cu-NOTA-pentixather and 64Cu-T140 deriva-
tives, uptake in the liver was mostly specific; therefore, the authors suggest a CXCR4-
independent component (Jacobson et al. 2009). Moreover, as tested by [64Cu]CuCl2
injected mice, transchelation did not contribute to the increased uptake in kidneys or
liver. However, after 10 h, % ID/g values in the blood increased which hints towards
transchelation at delayed time points (De Silva et al. 2011).
In the case of [64Cu]NOTA-pentixather, the overall high stability is also reflected by
increasing tumor-to-blood ratios, which, accompanied with its promising CXCR4-
targeting properties, resulted in high-contrast PET/CT images of lymphoma xenografts
(Fig. 5). As shown in TACs, tumor uptake was higher than activity accumulation in all
other tissues already at 17 min p.i., highlighting the efficient CXCR4-targeting and fast
clearance of the tracer from non-target tissue with comparably low unspecific back-
ground accumulation at all time points (Fig. 6). However, at 1.5 and 3.5 h p.i, some
background accumulation in the excretion organs was still visible. As discussed, this
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overall clearance due to the enhanced lipophilicity of the tracer compared to
[68Ga]pentixafor. At 24 h p.i., tracer clearance from the body is almost complete, result-
ing in very low residual activity in liver and tumor. Modest internalization and fast
externalization kinetics (Fig. 2) contribute to the fast clearance from tumor tissue.
Although, its use for endoradiotherapeutic purposes is therefore limited, [64Cu]NOTA-
pentixather proved as valuable PET agent for imaging of CXCR4 expression in vivo.Conclusion
In summary we were able to successfully transfer our ‘pentixafor/pentixather’-based
CXCR4-targeting technology to a promising analog for 64Cu-labeling. Due to the suit-
able in vitro and in vivo stability of the tracer, its rapid and specific activity accumula-
tion in the Daudi xenograft, as well as rapid clearance from the background, PET
images resulted in a clear delineation of the experimental tumors in vivo. However, fast
clearance from the human xenografts and some uptake in the excretory organs, attrib-
uted to its slightly enhanced lipophilicity, limit the tracer’s efficiency for a further thera-
peutic transfer with 67Cu. The initial results recommend further investigations with
[64Cu]NOTA-pentixather for CXCR4-PET imaging.Methods
General procedures and syntheses of the peptides were performed as described
(Poschenrieder et al. 2016b).[natCu]NOTA-pentixather
The non-radioactive reference compound [natCu]NOTA-pentixather was prepared by
mixing a 2 mM solution of NOTA-pentixather (250 μL) with an equal volume of 2 mM
Cu(OAc)2 (pH = 6.0) and allowing the complexation reaction to proceed at room
temperature (RT) for 30 min. Quantitative complex formation was confirmed by HPLC
analysis.
HPLC (30 to 55%B in 15 min): tR = 12.3 min; calculated monoisotopic mass for [
natCu]-
NOTA-pentixather (C56H70CuIN13O12): 1306.4; found (ESI-MS): m/z = 1307.7 [M +H]
+.[natCu]NODAGA-pentixather
The non-radioactive reference compound [natCu]NODAGA-pentixather was prepared
as described above. Quantitative complex formation was confirmed by HPLC analysis.
HPLC (30 to 55%B in 15 min): tR = 12.3 min; calculated monoisotopic mass for [
natCu]-
NOTA-pentixather (C59H74CuIN13O14): 1378.4; found (ESI-MS): m/z = 1379.8 [M +H]
+.64Cu-labeling of NOTA-pentixather
[64Cu]CuCl2 in 0.1 M HCl was obtained from the University of Tübingen. For peptide
radiolabeling, 25 μL of [64Cu]CuCl2 (273 MBq) were added to an aqueous solution con-
taining 150 μL 0.4 M NaOAc buffer (pH = 5.5) and 5 nmol of NOTA-pentixather. After
heating to 60 °C for 10 min, the reaction mixture was allowed to cool to RT, and
[64Cu]NOTA-pentixather was isolated via solid phase extraction using a C8-light
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of ethanol containing 0.5% (v/v) acetic acid.EDTA-challenge
For challenging experiments, 4 MBq of [64Cu]NOTA-pentixather were incubated in
0.1 M EDTA at different pH values (2.5 and 7.4) for a minimum of 24 h. At specific
time points, samples were analyzed via radio-TLC using silica gel impregnated
chromatography paper (Agilent Technologies, CA, USA) and 0.1 M phosphate buffer
(pH = 7.4) containing 10 mM sodium EDTA as the mobile phase.Determination of lipophilicity and serum stability
The lipophilicity and serum stability of [64Cu]NOTA-pentixather were determined as
described previously (Poschenrieder et al. 2016a). Briefly, to a solution of app. 2 kBq of
radiolabelled peptide in 500 μL of PBS (pH 7.4), 500 μL of octanol were added (n = 6).
Vials were vortexed vigorously for 3 min. To achieve quantitative phase separation, the
vials were centrifuged at 14,600 · g for 6 min in a Biofuge 15 (Heraeus Sepatech, Oster-
ode, Germany). The activity concentrations in 100 μL samples of both the aqueous and
the organic phase were measured in a gamma counter, and the log Pow was calculated.In vitro studies
CXCR4 affinities were determined using Jurkat T-cell leukemia cells and [125I]FC131 as
the radioligand (Poschenrieder et al. 2016b). Briefly, cells (4 × 105 cells per vial) were
incubated with app. 0.1 nM of [125I]FC131 in the presence of varying concentrations
(10−11 to 10−5 M) of the respective peptide of interest (n = 3 samples/concentration) for
120 min at RT. After centrifugation and repeated washing steps, the amount of free
and bound radioligand were quantified for each sample using a γ-counter, and IC50
values were calculated using GraphPad Prism 6.01 software.
Internalization and efflux studies were performed as described (Poschenrieder et al.
2016a) using Chem-1 cells stably transfected with hCXCR4 (HTS004C, Merck Millipore,
Darmstadt, Germany). Briefly, adherent cells in 24-well plates (150,000/well) were incu-
bated with 1 nM [64Cu]NOTA-pentixather in the absence (total binding) or presence of
100 μM AMD3100 (non-specific binding) at 37 °C for different time intervals up to
60 min. Subsequently, the amount of free, membrane-bound, and internalized activity
were quantified for each sample using a γ-counter. For efflux studies, [64Cu]NOTA-pen-
tixather was first allowed to internalize at 37 °C for 45 min. Then, the supernatant was
exchanged by ligand-free assay medium, and efflux of [64Cu]NOTA-pentixather over time
was investigated (37 °C). The remaining total cellular activity (membrane-bound + inter-
nalized activity) at different time points was quantified as described above.In vivo studies
All animal studies were approved by the local authorities (No.: 55.2-1-54-2532-71-13)
and are in compliance with the institution’s guidelines. For metabolite analysis, 18 MBq
of [64Cu]NOTA-pentixather in a total volume of 200 μL of phosphate-buffered saline
(PBS) were injected into the tail vein of a CB17 SCID mouse. At 1 h p.i., the animal
Poschenrieder et al. EJNMMI Radiopharmacy and Chemistry  (2017) 2:2 Page 12 of 14was sacrificed and blood, urine, kidneys, and liver were collected. After sample prepar-
ation (Weineisen et al. 2014), the samples were analyzed by reversed phase (RP)-HPLC.
For PET and biodistribution studies, an average of 5.2 MBq [64Cu]NOTA-pentixather
(200 μL in PBS, 122 pmol, 160 ng) with a SA of 43 GBq/μmol was injected intravenously
into the tail vein of isofluorane anaesthesized female Daudi (human B-cell lymphoma)
xenograft bearing CB17 SCID mice. CXCR4-specificity of [64Cu]NOTA-pentixather up-
take was demonstrated by coinjection of 2 mg/kg AMD3100. PET imaging with
[64Cu]NOTA-pentixather under ‘tracer only’ (n = 2) as well as blocking conditions (coin-
jection of 2 mg/kg AMD3100, n = 1) was performed at three different time points
(dynamic PET imaging for 1 h, followed by static image acquisition for 15 min after 3.5
and 24 h) using an Inveon Siemens μPET scanner. PET/CT images were reconstructed by
a two-dimensional ordered subset expectation maximum (2D-OSEM) algorithm with no
attenuation correction. Image analysis was performed using the Inveon software, and
results were calculated as %ID/g. For biodistribution studies, the mice were sacri-
ficed at 1.5 h (n = 5) and 24 h (n = 6) p.i., tissues and organs of interest were
dissected, weighed, and counted for radioactivity in a γ-counter. The percentage of
injected dose per gram of tissue (% ID/g) was calculated; data are presented as
mean ± SD.
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